Literature DB >> 24721826

Napsin A is a specific marker for ovarian clear cell adenocarcinoma.

Yoriko Yamashita1, Tetsuro Nagasaka2, Aya Naiki-Ito3, Shinya Sato3, Shugo Suzuki3, Shinya Toyokuni4, Masafumi Ito5, Satoru Takahashi3.   

Abstract

Ovarian clear cell adenocarcinoma has a relatively poor prognosis among the ovarian cancer subtypes because of its high chemoresistance. Differential diagnosis of clear cell adenocarcinoma from other ovarian surface epithelial tumors is important for its treatment. Napsin A is a known diagnostic marker for lung adenocarcinoma, and expression of napsin A is reported in a certain portion of thyroid and renal carcinomas. However, napsin A expression in ovarian surface epithelial tumors has not previously been examined. In this study, immunohistochemical analysis revealed that in 71 of 86 ovarian clear cell adenocarcinoma patients (83%) and all of the 13 patients with ovarian clear cell adenofibroma, positive napsin A staining was evident. No expression was observed in 30 serous adenocarcinomas, 11 serous adenomas or borderline tumors, 19 endometrioid adenocarcinomas, 22 mucinous adenomas or borderline tumors, 10 mucinous adenocarcinomas, or 3 yolk sac tumors of the ovary. Furthermore, expression of napsin A was not observed in the normal surface epithelium of the ovary, epithelia of the fallopian tubes, squamous epithelium, endocervical epithelium, or the endometrium of the uterus. Therefore, we propose that napsin A is another sensitive and specific marker for distinguishing ovarian clear cell tumors (especially adenocarcinomas) from other ovarian tumors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24721826     DOI: 10.1038/modpathol.2014.61

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  49 in total

1.  Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.

Authors:  Akira Tsuchiya; Michiie Sakamoto; Jun Yasuda; Makoto Chuma; Tsutomu Ohta; Misao Ohki; Toshiharu Yasugi; Yuji Taketani; Setsuo Hirohashi
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

2.  Napsin A expression in pulmonary sclerosing haemangioma.

Authors:  Giulio Rossi; Annamaria Cadioli; Maria Cecilia Mengoli; Silvia Piccioli; Alberto Cavazza
Journal:  Histopathology       Date:  2011-11-10       Impact factor: 5.087

3.  Napsins: new human aspartic proteinases. Distinction between two closely related genes.

Authors:  P J Tatnell; D J Powell; J Hill; T S Smith; D G Tew; J Kay
Journal:  FEBS Lett       Date:  1998-12-11       Impact factor: 4.124

4.  Human napsin A: expression, immunochemical detection, and tissue localization.

Authors:  V Schauer-Vukasinovic; D Bur; D Kling; F Grüninger; T Giller
Journal:  FEBS Lett       Date:  1999-11-26       Impact factor: 4.124

5.  Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases.

Authors:  Deborah DeLair; Esther Oliva; Martin Köbel; Antonio Macias; C Blake Gilks; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2011-01       Impact factor: 6.394

6.  Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers.

Authors:  Atsuhiko Toyama; Atsushi Suzuki; Takashi Shimada; Chikage Aoki; Yutaka Aoki; Yukari Umino; Yusuke Nakamura; Daisuke Aoki; Taka-Aki Sato
Journal:  Cancer Sci       Date:  2012-02-20       Impact factor: 6.716

7.  Applications and limitations of immunohistochemical expression of "Napsin-A" in distinguishing lung adenocarcinoma from adenocarcinomas of other organs.

Authors:  Maryam Kadivar; Behnaz Boozari
Journal:  Appl Immunohistochem Mol Morphol       Date:  2013-05

8.  Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type.

Authors:  Elvio G Silva; Robert H Young
Journal:  Am J Surg Pathol       Date:  2007-08       Impact factor: 6.394

9.  Immunohistochemical localization of napsin and its potential role in protein catabolism in renal proximal tubules.

Authors:  Koshi Mori; Hidemi Shimizu; Akihiro Konno; Toshihiko Iwanaga
Journal:  Arch Histol Cytol       Date:  2002-10

10.  Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma.

Authors:  T Ueno; S Linder; G Elmberger
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more
  19 in total

Review 1.  Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Authors:  W Glenn McCluggage; Meagan J Judge; Blaise A Clarke; Ben Davidson; C Blake Gilks; Harry Hollema; Jonathan A Ledermann; Xavier Matias-Guiu; Yoshiki Mikami; Colin J R Stewart; Russell Vang; Lynn Hirschowitz
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

2.  High-level expression of divergent endodermal lineage markers in gonadal and extra-gonadal yolk sac tumors.

Authors:  Hadi Shojaei; Hong Hong; Raymond W Redline
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

3.  Diagnostic value of dual detection of hepatocyte nuclear factor 1 beta (HNF-1β) and napsin A for diagnosing ovarian clear cell carcinoma.

Authors:  Qing Li; Xin Zeng; Xue Cheng; Jingmin Zhang; Jie Ji; Jinsong Wang; Kemei Xiong; Qiong Qi; Wenbin Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

4.  Napsin A Expression in Subtypes of Thyroid Tumors: Comparison with Lung Adenocarcinomas.

Authors:  Jianghua Wu; Yanhui Zhang; Tingting Ding; Runfen Cheng; Wenchen Gong; Yuhong Guo; Ye Luo; Yi Pan; Qiongli Zhai; Wei Sun; Dongmei Lin; Baocun Sun
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

5.  Napsin-A and AMACR are Superior to HNF-1β in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract.

Authors:  Jennifer Pors; Sheila Segura; Angela Cheng; Jennifer X Ji; Basile Tessier-Cloutier; Dawn Cochrane; Daniel J Fix; Kay Park; Blake Gilks; Lynn Hoang
Journal:  Appl Immunohistochem Mol Morphol       Date:  2020-09

6.  Identification of biomarkers for the diagnosis and targets for therapy in patients with clear cell ovarian cancer: a systematic literature review.

Authors:  Holly Butler; Omar Saulat; Barbara-Ann Guinn
Journal:  Carcinogenesis       Date:  2022-04-25       Impact factor: 4.741

Review 7.  Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.

Authors:  Yoriko Yamashita
Journal:  Jpn J Clin Oncol       Date:  2015-01-12       Impact factor: 3.019

Review 8.  Pathobiology of ovarian carcinomas.

Authors:  Mojgan Devouassoux-Shisheboran; Catherine Genestie
Journal:  Chin J Cancer       Date:  2015-01

Review 9.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

10.  Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases.

Authors:  Bingjian Lu; Qin Chen; Xiaofei Zhang; Lili Cheng
Journal:  Diagn Pathol       Date:  2016-06-04       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.